Last reviewed · How we verify
Aripiprazole, oral formulation
At a glance
| Generic name | Aripiprazole, oral formulation |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
- The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia (PHASE4)
- European Long-acting Antipsychotics in Schizophrenia Trial (PHASE4)
- PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia (PHASE1)
- A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (PHASE2)
- Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers (PHASE1)
- Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants (PHASE1)
- Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aripiprazole, oral formulation CI brief — competitive landscape report
- Aripiprazole, oral formulation updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI